AstraZeneca/Daiichi Sankyo’s Next ADC Shows Promise In Triple-Negative Breast Cancer

Aiming To Overhaul Gilead’s Trodelvy

 
• By Andrew McConaghie
  
AstraZeneca
AstraZeneca and Daiichi Sankyo are looking to repeat the success seen with Enhertu • Source: Shutterstock: Elzbieta Krzysztof
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas